DS

Debbie Shawcross

Research areas: Medicine · Hepatology · Liver Disease and Transplantation · Alcohol Consumption and Health Effects · Liver Disease Diagnosis and Treatment

ORCID iD 0000-0001-6133-4619
Follow

About

I am a Clinician Scientist and Professor of Hepatology and Chronic Liver Failure based at the Roger Williams Institute of Liver Studies, King’s College London, King's College Hospital NHS Foundation Trust and Foundation for Liver Research. I work as a Consultant Hepatologist on the King’s College Hospital Liver Unit with a specialist interest in hepatic encephalopathy and the complications of cirrhosis.

I am an internationally recognised liver specialist and passionate advocate for tackling the growing burden of chronic liver disease. Frequently featured on TV, radio, and in print, I speak out on the dangers of excessive alcohol use and the urgent need for prevention and early detection of liver disease.

I was elected to the European Association for the Study of the Liver (EASL) Scientific Committee and Governing Board in October 2022 and am currently serving as its first female Secretary General.

As an advocate for high quality education and training in gastroenterology and hepatology I served as a Health Education England London Gastroenterology Training Programme Director for 10 years serving on the British Society Gastroenterology (BSG) Specialist Advisory Committee and Training Committee, BSG Mentor and an active member of the BSG Supporting Women in Gastroenterology. I have recently completed a 4-year term as Chair of the BSG Research Committee and sat on the BSG Executive Committee and Council and served as a Trustee for GUTS UK Charity. I am a Clinical Advisor for the British Liver Trust (Liver UK).

My research programme characterises the immunobiology of chronic liver failure focusing specifically on the gut-liver-brain axis in the context of the gut microbiome as a driver of immune dysfunction, inflammation and encephalopathy. I am a global leader the field in clinical trials of faecal microbiota transplantation (FMT) and am a Chief Investigator of the NIHR-funded EME UK multicentre randomised placebo-controlled clinical trial of FMT (capsules) [PROMISE Trial] in patients with metabolic dysfunction-associated and alcohol-related cirrhosis.

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications

Publications are unavailable.